VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells

Journal of Neuroimmunology

Volumn 96, Issue 2, 1999, Pages 167-181

  Delgado, Mario ^a,b   Munoz Elias, Ernesto J ^a   Gomariz, Rosa P ^b   Ganea, Doina ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cytokines; Endotoxin; Immune cells; Neuroimmunomodulation; Neuropeptides

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; IMMUNOMODULATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ENDOTOXEMIA; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; T-LYMPHOCYTES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033519349     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00023-5     Document Type: Article

References (69)

1. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal peptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:1996;5-27.
2. Calvo J.R., Pozo D., Guerrero J.M. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent systems. Adv. Neuroimmunol. 6:1996;39-47.
3. D'Andrea A., Rengaraju M., Valiante N.M., Chehimi J., Kubin M., Aste-Amezaga M., Chan S.H., Kobayashi M., Young D., Nickbarg E., Chizzonite R., Wolf S.F., Trinchieri G. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1992;1387-1398.
4. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J. Exp. Med. 178:1993;1041-1048.
5. DeKruyff R.H., Gieni R.S., Umetsu D.T. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J. Immunol. 158:1997;359-366.
6. De la Fuente M., Delgado M., Gomariz R.P. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:1996;75-91.
7. Delgado M., Pozo D., Martinez C., Garrido E., Leceta J., Calvo J.R., Gomariz R.P. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:1996;161-166.
8. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNFα transcriptional activation by regulating NFkB and CREB/c-Jun. J. Biol. Chem. 273:1998;31427-31436.
9. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNFα production by macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;2358-2367.
10. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., Gomariz R.P. VIP and PACAP protect mice from lethal endotoxemia through the inhibition of TNFα and IL-6. J. Immunol. 162:1999;1200-1205.
11. Delgado M., Munoz-Elias E.J., Gomariz R.P., Gamea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;1707-1716.
12. Delgado, M., Munoz-Elias, E.J., Gomariz, R.P., Ganea, D., 1999d. VIP and PACAP prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and interferon regulatory factor 1 activation. J. Immunol., in press.
13. Dewit D., Gourlet P., Amraoui Z., Vertongen P., Willems F., Robberecht P., Goldman M. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 60:1998;57-60.
14. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Buresh C.M., Norton J.A. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 149:1992;1666-1670.
15. Fiorentino D.F., Zlotnik A., Mossman T.R., Howard M., O'Garra A. Interleukin-10 inhibits cytokine production by activated macrophages. J. Immunol. 714:1991;3815-3822.
16. Flesch I.E., Hess J.H., Huang S., Aguet M., Rothe J., Bluethmann H., Kufmann S.H. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J. Exp. Med. 181:1995;1615-1621.
17. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:1996;61-74.
18. Gaytan F., Martinez-Fuentes A.J., Gracia-Navarro F., Vaudry H., Aguilar E. Pituitary adenylate cyclase activating polypeptide (PACAP) immunolocalization in lymphoid tissues of the rat. Cell Tissue Res. 276:1994;223-227.
19. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:1993;547-550.
20. Gourlet P., Vandermeers-Piret M.C., Rathe J., De Neef P., Robberecht P. Fragments of the pituitary adenylate cyclase-activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287:1995;7-11.
21. Gourlet P., Vilardaga J.-P., De Neef P., Waelbroeck M., Vandermeers A., Robberecht P. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides. 17:1996;825-829.
22. Gourlet P., Vandermeers A., Vertongen P., Ratche J., De Neef P., Cnudde J., Waelbroeck G., Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545.
23. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides. 18:1997;1555-1560.
24. Gubler U., Chua A.O., Schoenhaunt D.S., Dwyer C.M., McComas W., Motyka R., Nabavi N., Wolitzky A.G., Quinn P.M., Familletti P.C., Gately M.K. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4143-4147.
25. Hamar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Washeck J.A. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:1998;625-627.
26. Haraguchi S., Good R.A., Day N.K. Immunosuppresive retroviral peptides: cAMP and cytokine patterns. Immunol. Today. 16:1995;595-603.
27. Heinzel F.P., Rerko R.M., Ling P., Hakimi J., Schoenhaut D.S. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect. Immun. 62:1994;4244-4249.
28. Hernanz A., Tato E., De la Fuente M., De Miguel E., Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. 75:1996;25-30.
29. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1993;1205-1208.
30. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:1993;547-549.
31. Kaltreider H.B., Ichikawa S., Byrd P.K., Ingram D.A., Kishiyama J.L., Sreedharan S.P., Warnock M.L., Beck J.M., Goetzl E.J. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am. J. Respir. Cell Mol. Biol. 16:1997;133-144.
32. Kincy-Cain T., Bost K.L. Substance P-induced IL-12 production by murine macrophages. J. Immunol. 158:1997;2334-2339.
33. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170:1989;827-846.
34. Kunkel S.L., Spengler M., May M.A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:1988;5380-5384.
35. Laskin D.L., Pendino J.K. Macrophages and inflammatory mediators in tissue injury. Annu. Rev. Pharmacol. Toxicol. 35:1995;655-677.
36. Leceta J., Martinez C., Delgado M., Garrido E., Gomariz R.P. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol. 6:1996;29-36.
37. Ma X., Neurath M., Gri G., Trinchieri G. Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J. Biol. Chem. 272:1997;10389-10395.
38. Magram J., Connaughton S.E., Warrier R.R., Carvajal D.M., Wu C.W., Ferrante J., Stewart C., Sarmiento U., Faherty D.A., Gately M.K. IL-12 deficient mice are defective in IFNγ production and type 1 cytokine responses. Immunity. 4:1996;471-481.
39. Manetti R., Parronchi P., Guidizi M.G., Piccinni M., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J. Exp. Med. 177:1993;1199-1204.
40. Marchant A., Bruyns C., Vandenabeele P., Ducarme M., Gerard C., Delvaux A., De Groote D., Abramowicz D., Velu T., Goldman M. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24:1994;1167-1171.
41. Martinez C., Delgado M., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:1996;4128-4136.
42. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukocyte Biol. 63:1998;591-601.
43. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93:1999;126-138.
44. Moro O., Lerner E.A. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J. Biol. Chem. 271:1996;966-970.
45. Muchamuel T., Menon S., Pisacane P., Howard M.C., Cockayne D.A. IL-13 protects mice from LPS-induced lethal endotoxemia. J. Immunol. 158:1997;2898-2903.
46. Murphy T.L., Cleveland M.G., Kulesza P., Magram J., Murphy K.M. Regulation of interleukin 12 p40 expression through an NF-kB half-site. Mol. Cell. Biol. 15:1995;5258-5267.
47. Muscettola M., Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology. 180:1990;419-430.
48. O'Donnell M., Garippa R.J., O'Neill N.C., Bolin D.R., Cottrell J.M. Structure-activity studies of vasoactive intestinal polypeptide. J. Biol. Chem. 266:1991;6389-6392.
49. Panina-Bordignon P., Mazzeo D., Lucia P.D., D'Ambrosio D., Lang R., Fabbri R., Self C., Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 15:1997;1513-1519.
50. Pozo D., Delgado M., Martinez C., Gomariz R.P., Guerrero J.M., Calvo J.R. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor in rat peritoneal macrophages. Biochim. Biophys. Acta. 1359:1997;250-262.
51. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr. Rev. 17:1996;4-29.
52. Skeen M.J., Miller M.A., Shinnick T.M., Ziegler H.K. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156:1996;1196-1206.
53. - αβ T cells in the peritoneal cavity. Specific T cell-receptor mediated cytotoxicity and selective IFNg production against B cell leukemia and myeloma cells. J. Immunol. 157:1996;3925-3935.
54. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
55. Trepicchio W., Bozza M., Pedneault G., Dorner A. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157:1996;3627-3634.
56. Trinchieri G. Interleukin 12: a proinflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:1995;251-278.
57. Trinchieri G. Immunobiology of interleukin-12. Immunol. Res. 17:1998;269-278.
58. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int. Rev. Immunol. 16:1998;365-396.
59. Tripp C.S., Wolf S.F., Unanue E.R. Interleukin-12 and tumor necrosis factor-a are costimulators of interferon-g production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiological antagonist. Proc. Natl. Acad. Sci. U.S.A. 90:1993;3725-3729.
60. Tsunawaki S., Sporn M., Ding A., Nathan C.F. Deactivation of macrophages by transforming growth factor β Nature. 334:1988;260-262.
61. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:1995;775-779.
62. van Deuren M., Dofferhoff A.S.M., van der Meer J.W.M. Cytokines and the response to infection. J. Pathol. 168:1992;349-356.
63. Wang H.Y., Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:1996;3243-3253.
64. Wolf S., Seiburth D., Perussia B., Yetz-Adalpe J., D'Andrea A., Trinchieri G. Cell sources of natural killer cell stimulatory factor (NKSF/IL-12) transcripts and subunit expression. FASEB J. 6:1992;A1335.
65. Wysocka M., Kubin M., Vieira L.Q., Ozmen L., Garotta G., Scott P., Trinchieri G. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25:1995;672-676.
66. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:1997;629-633.
67. Xin Z., Sriram S. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J. Neuroimmunol. 89:1998;206-212.
68. Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via TCR/CD3 complex. J. Neuroimmunol. 54:1994;59-68.
69. Yoshimoto T., Kojima K., Funakoshi T., Endo Y., Fujita T., Nariuchi H. Molecular cloning and characterization of murine IL-12 genes. J. Immunol. 156:1996;1082-1088.